Allogene Therapeutics is a clinical-stage biotechnology company dedicated to pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for patients with cancer. They are focused on creating 'off-the-shelf' AlloCAR T™ products, which are designed to be readily available for a broad patient population, overcoming the logistical and manufacturing complexities of autologous CAR T therapies. Their pipeline targets various hematologic malignancies and solid tumors, leveraging advanced gene editing technologies and manufacturing processes.
The headquarters serves as the central hub for corporate operations, research and development (R&D), clinical development, and strategic planning for its allogeneic cell therapy programs.
The facility includes state-of-the-art research laboratories, process development labs, and office spaces designed to foster innovation in cell therapy. While a separate manufacturing facility exists, the HQ is critical for early-stage R&D and process optimization.
The work culture at Allogene Therapeutics is characterized by a strong emphasis on scientific innovation, collaboration, patient focus, and a fast-paced environment typical of clinical-stage biotechnology companies aiming to bring novel therapies to market.
The South San Francisco headquarters is strategically important due to its location within a leading global biotech cluster, providing access to talent, research institutions, and a network of collaborators. It's the nerve center for advancing the company's AlloCAR T™ platform.
Allogene Therapeutics's primary operations are based in the United States, with its headquarters and R&D in South San Francisco and manufacturing in Newark, CA. Its global presence is mainly characterized by the conduct of multi-center clinical trials for its AlloCAR T™ candidates, which may involve sites across North America, Europe, and potentially other regions as its programs advance. The company also engages in global collaborations for research and technology access.
210 East Grand Avenue
South San Francisco
CA
USA
Address: Newark, California (Specific street address for manufacturing facility not broadly publicized)
Strategically located in the San Francisco Bay Area, this facility supports the company's need for scalable, in-house manufacturing capabilities, ensuring control over production and supply chain for its innovative cell therapy products.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Allogene Therapeutics' leadership includes:
Allogene Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months (May 2023 - May 2024), Allogene Therapeutics has seen key leadership changes, notably in its technical and legal departments, with new appointments to Chief Technical Officer and General Counsel, and corresponding departures.
Discover the tools Allogene Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Allogene Therapeutics commonly uses the 'first.last' email format for its employees. Other potential formats could exist but this is the most frequently observed.
first.last@allogene.com
Format
jane.doe@allogene.com
Example
85%
Success rate
Allogene Therapeutics Press Release • May 23, 2024
Allogene announced it will present updated data from its Phase 1 ALPHA2 study of cema-cel (ALLO-501A) in patients with relapsed/refractory Large B Cell Lymphoma at the upcoming ASCO 2024 meeting....more
Allogene Therapeutics Press Release • May 7, 2024
Allogene provided an update on its pipeline progress, including its CAR T cell therapy candidates, and reported its financial results for the first quarter ending March 31, 2024....more
Allogene Therapeutics Press Release • April 17, 2024
Allogene announced the publication of positive data from its Phase 1 ALPHA/ALPHA2 trials of ALLO-501 and ALLO-501A in relapsed/refractory non-Hodgkin lymphoma in the peer-reviewed journal The Lancet....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Allogene Therapeutics, are just a search away.